Rituximab, a chimeric IgG1 monoclonal antibody that binds to CD20 antigen expressed on B lymphocytes, is approved in adults for several immune-mediated inflammatory diseases (IMIDs), including rheumatoid arthritis (RA), antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV), granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and pemphigus vulgaris. It is also used as off-label treatment for autoimmune diseases such as systemic lupus erythematosus (SLE).
Mulleman et al. (Wed,) studied this question.